News Search Results
Jan 20, 2026, 07:45 ET Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 20, 2026, 07:00 ET Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Jan 20, 2026, 07:00 ET Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System
point-of-care assessment of suspicious moles and early detection of melanoma-related activity. The results of the study conducted by Orlucent, a biotechnology company developing solutions for the non-invasive detection of melanoma activity, were published in the February edition of the peer-reviewed Journal
More news about: Orlucent, Inc.
Jan 20, 2026, 06:26 ET Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Jan 20, 2026, 05:09 ET GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation
products, GENEIII continues to define what clinically validated, world-class ergothioneine truly means.About GeneIIIAt GeneIII, we are a biotechnology company at our core. Our patented bioengineering process redefines L-Ergothioneine production, delivering 99.99% purity, full transparency, and
More news about: GENEIII
Jan 20, 2026, 04:17 ET Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational Services
BEIJING, Jan. 20, 2026 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd., a leading biotechnology company, today announced the launch of its redesigned global website, aimed at simplifying access to its comprehensive biotech R&D and translational
More news about: Beijing Tsingke Biotech Co., Ltd.
Jan 20, 2026, 04:00 ET Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
inhibitory polypeptide receptor, GCGR: glucagon receptorAbout Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 19, 2026, 17:31 ET Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight
companies including Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc., Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany
More news about: DelveInsight Business Research, LLP
Jan 19, 2026, 12:10 ET The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
DOSEF) (FSE: VU70) is a biotechnology company developing oral delivery platforms for modern stimulants, positioning itself within a consumer shift away from traditional energy drinks,
More news about: Baystreet
Jan 19, 2026, 08:32 ET Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week
also featured a pitch session with Luca Emili (Chairman, InSilicoTrials Technologies), Massimiliano Clamer, PhD (Chairman, Immagina Biotechnology), Enzo Troncone (CEO and founder, Butterfly Decisions) and Leandro Agrò (Relationship Manager, It's Prodigy), followed by a networking
More news about: Italian Trade Agency
Jan 19, 2026, 08:00 ET FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its lead product, NouvNeu001, has been granted Regenerative
More news about: iRegene Therapeutics Co., Ltd
Jan 19, 2026, 06:19 ET MGI Tech empowers the University of Lisbon to study impact of Saharan dust on Portuguese agriculture -Vineyards as Key Case Study
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology.We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and
More news about: MGI Tech Co., Ltd.
Jan 18, 2026, 20:00 ET D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared
More news about: D3 Bio
Jan 18, 2026, 19:02 ET Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
warrant was originally issued to Harbour BioMed's subsidiary and other minority shareholders of HBM Alpha Therapeutics ("HBMAT"), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration
More news about: Harbour BioMed
Jan 16, 2026, 18:22 ET 2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements
capital, and technology. A complete industrial chain spanning early-stage R&D to clinical production is gradually taking shape, while a cohort of biotechnology companies with global vision is rapidly emerging, providing full-chain support for innovative drug development.From their collective presence
More news about: Beijing Hotgen Biotech Co., Ltd.
Jan 16, 2026, 16:01 ET MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of
More news about: MetaVia Inc.
Jan 16, 2026, 11:01 ET Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors
16, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced that it has filed its Annual Information Form ("AIF"), a key Canadian public-company disclosure
More news about: Doseology Sciences Inc.
Jan 16, 2026, 09:20 ET Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
engagement, combined with high safety and tolerability, is essential."About Vaximm AGVaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell immunotherapy platform harnesses live, attenuated
More news about: OSR Holdings
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
product revenue of approximately $113 million for fiscal year 2025, representing a 700% year-over-year increase for ANKTIVA. The commercial-stage biotechnology company delivered fourth quarter preliminary revenue of approximately $38.3 million, marking a 20% sequential increase and a 431% year-over-year
More news about: Equity Insider
Jan 16, 2026, 05:05 ET Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs
GroupFounded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer
More news about: Datwyler
Jan 16, 2026, 03:30 ET Digital Pathology Market Growing at 9.9% CAGR to 2031 as AI Adoption Accelerates, says a 2026 Mordor Intelligence Report
& Archiving By End User Hospital & Reference Laboratories Pharmaceutical & Biotechnology Companies and CROs Diagnostic Centers Other End Users By Deployment Model On-premise Cloud-based
More news about: Mordor Intelligence Private Limited
Jan 15, 2026, 23:23 ET The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification
Jan. 15, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became the first domestic
More news about: XinTianhe Biotechnology
Jan 15, 2026, 12:00 ET QuantiPath Introduces Expanded À La Carte Multiplex Options
requirements — from high-throughput screening programs to localized investigative testing scenarios.About QuantiPathQuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHx, is the only rapid test kit that
More news about: QuantiPath
Jan 15, 2026, 10:43 ET Cancer Biomarkers Market Surges to USD 45.7 Billion by 2033, Propelled by 8.6% CAGR - Verified Market Reports®
large patient populations, increasing cancer incidence, and expanding access to diagnostic services. National health reforms and investments in biotechnology infrastructure are enabling local companies to enter the biomarker value chain. Countries such as China, Japan, and South Korea are prioritizing
More news about: Verified Market Reports
Jan 15, 2026, 10:30 ET Drug Discovery Technologies Market worth $51.51 billion by 2031 | MarketsandMarkets™
biological targets. The technology has immense applications in the drug discovery stages of organizations associated with the pharmaceutical and biotechnology industries.Request Sample Pages@
More news about: MarketsandMarkets